Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT00782145 Completed - Lymphoma Clinical Trials

A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

Start date: June 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's quality of life. PURPOSE: This randomized phase III trial is studying a Web-based stem cell transplant support system to see how well it works compared with standard care in families of young patients undergoing a stem cell transplant.

NCT ID: NCT00778375 Completed - Clinical trials for Acute Myeloid Leukemia

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older. The safety of this treatment will also be studied.

NCT ID: NCT00776503 Completed - Clinical trials for Myelodysplastic Syndromes

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

GFMVOR2007
Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.

NCT ID: NCT00774280 Completed - Leukemia Clinical Trials

Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen

BuCyvsBUFlu
Start date: May 2002
Phase: Phase 3
Study type: Interventional

1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8.

NCT ID: NCT00774046 Completed - Clinical trials for Acute Myeloid Leukemia

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Start date: December 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.

NCT ID: NCT00764829 Completed - Leukemia Clinical Trials

Blood Samples to Evaluate Biomarkers of Donor Chimerism

Start date: September 2008
Phase: N/A
Study type: Observational

We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.

NCT ID: NCT00761722 Completed - Multiple Myeloma Clinical Trials

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

RACE
Start date: August 12, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.

NCT ID: NCT00760084 Completed - Clinical trials for Myelodysplastic Syndrome

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.

NCT ID: NCT00750009 Completed - Lymphoma Clinical Trials

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Start date: April 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial. It is not known whether providing personalized information is more effective than basic information in helping patients make decisions about clinical trials. PURPOSE: This randomized phase III trial is studying personalized information to see how well it works compared with basic information in helping patients make decisions about participating in a clinical trial.

NCT ID: NCT00749372 Completed - Clinical trials for Myelodysplastic Syndrome (MDS)

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

T2*MRI
Start date: July 31, 2008
Phase: N/A
Study type: Interventional

A known risk of red blood cell transfusions is that it puts excess iron into the patient's body. Researchers are continually seeking the most effective method of measuring iron concentration. The purpose of this study is to determine how much iron has been deposited in a patient's heart and liver as a result of having received red blood cell transfusions using magnetic resonance imaging (MRI).